This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Impaired synaptic plasticity and dendritic loss in excitatory glutamatergic synapses are early events in Alzheimer disease (AD). These synaptic abnormalities are triggered by accumulation of soluble fibrillary β-amyloid (Aβ) oligomers, which bind to several postsynaptic and presynaptic partners. Many of the synaptic effects of Aβ oligomers involve NMDA receptors (NMDARs) and type 1 metabotropic glutamate receptor 5 (mGluR5). These receptors mediate use-dependent plasticity of glutamatergic synapses in the hippocampus and other brain regions. Synaptic plasticity includes long-term potentiation (LTP) and long-term depression (LTD) of efficacy of synaptic transmission. Studies both in vitro and in animal models indicate that Aβ oligomers disrupt LTP and promote LTD; these effects are associated with decreased density of dendritic spines. The mechanisms by which Aβ oligomers elicit these synaptic changes are similar to those normally utilized in the CNS during development and learning. In addition, interactions of β oligomers with extrasynaptic NMDARs and mGluR5 promote tau-hyperphosphorylation, leading to impaired mitochondrial transport to synapses and thus disrupting calcium homeostasis and energy-dependent processes. Via activation of glial cells, Aβ triggers complement-mediated pruning of vulnerable synapses. Loss of dendritic spines precedes the accumulation of neuritic plaques and neurofibrillary tangles and is potentially reversible. The multiple potential mechanisms by which Aβ oligomers may trigger dysfunction and loss of glutamatergic synapses provide multiple targets for neuroprotective therapy. There are several reviews focused on these topics.1–11 Only selected aspects of synaptic plasticity and its involvement in AD are reviewed here.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the author, if any, are provided at the end of the article.
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
